99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of ABEO Investors. Click "Join this Class Action" above.

Attorneys

Abeona Therapeutics Inc.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) from May 31, 2018 through September 23, 2019 (the “Class Period”). The lawsuit seeks to recover damages for Abeona Therapeutics Inc. investors under the federal securities laws.

If you bought Abeona Therapeutics Inc. securities between May 31, 2018 through September 23, 2019, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Abeona Therapeutics Inc.– ABEO 

New York, N.Y., November 8, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) between May 31, 2018 and September 23, 2019, inclusive (the “Class Period”).

To join the ABEO class action, go to http://zhanginvestorlaw.com/cases/abeona-therapeutics-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.  YOU NEED NOT BE A LEAD PLAINTIFF TO OBTAIN COMPENSATION.

According to the lawsuit, throughout the Class Period: (1) Abeona’s Chemical, Manufacturing and Controls and internal controls and procedures and/or compliance policies were inadequate; (2) the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or such transport stability was insufficient; (3) it was foreseeable that the U.S. Food and Drug Administration would reject approval for the start of the VITAL Study until such issues were addressed; and (4) as a result, Abeona’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/abeona-therapeutics-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.